Surrozen (SRZN) Accounts Payables (2020 - 2026)
Surrozen (SRZN) recorded quarterly Accounts Payables of $889000.0 in Q1 2026, up 22.12% quarter-over-quarter from $728000.0 in Q4 2025, and up 194.37% on a YoY basis from $302000.0 in Q1 2025.
Surrozen (SRZN) Accounts Payables (2020 - 2026) Analysis & Trends
Surrozen's Accounts Payables history runs 7 years deep, the most recent figure standing at $889000.0 for Q1 2026.
- In Q1 2026, Accounts Payables rose 194.37% year-over-year to $889000.0; the TTM figure through Mar 2026 stood at $889000.0 (up 194.37% YoY), while the FY2025 annual figure was $728000.0, up 137.91% from the prior year.
- Accounts Payables was $889000.0 for Q1 2026 at Surrozen, up from $728000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.0 million in Q1 2022 to a low of $131000.0 in Q1 2024.
- Historically, Accounts Payables has averaged $432294.1 across 5 years, with a median of $354000.0 in 2025.
- The sharpest annual moves came in 2023 and 2026: Accounts Payables tumbled 83.64% in 2023, then jumped 194.37% in 2026.
- A 5-year view of Accounts Payables shows it stood at $658000.0 in 2022, then decreased by 20.21% to $525000.0 in 2023, then plunged by 41.71% to $306000.0 in 2024, then soared by 137.91% to $728000.0 in 2025, then climbed by 22.12% to $889000.0 in 2026.
- The last three Accounts Payables figures came in at $889000.0 (Q1 2026), $728000.0 (Q4 2025), and $538000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 8.64 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 34.55 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 889,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 889,000.00 |
| Dec 31, 2025 | 728,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Jun 30, 2025 | 354,000.00 |
| Mar 31, 2025 | 302,000.00 |
| Dec 31, 2024 | 306,000.00 |
| Sep 30, 2024 | 276,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Mar 31, 2024 | 131,000.00 |
| Dec 31, 2023 | 525,000.00 |
| Sep 30, 2023 | 287,000.00 |
| Jun 30, 2023 | 186,000.00 |
| Mar 31, 2023 | 171,000.00 |
| Dec 31, 2022 | 658,000.00 |
| Sep 30, 2022 | 362,000.00 |
| Jun 30, 2022 | 418,000.00 |
| Mar 31, 2022 | 1.05 Mn |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Dec 31, 2020 | 1.78 Mn |